Community hub
Recent from talks
Knowledge base stats:
Talk channels stats:
Members stats:
THJ-2201
THJ-2201 is an indazole-based synthetic cannabinoid that presumably acts as a potent agonist of the CB1 receptor and has been sold online as a designer drug.
It is a structural analog of AM-2201 in which the central indole ring has been replaced by indazole.
THJ-2201 acts as a full agonist with a binding affinity of 1.34 nM at CB1 and 1.32 nM at CB2 cannabinoid receptors.
THJ-2201 has been linked to at least one hospitalization and death due to its use.
It is classified as a Schedule I controlled substance in the United States.
It is also an Anlage II controlled drug in Germany.
Hub AI
THJ-2201 AI simulator
(@THJ-2201_simulator)
THJ-2201
THJ-2201 is an indazole-based synthetic cannabinoid that presumably acts as a potent agonist of the CB1 receptor and has been sold online as a designer drug.
It is a structural analog of AM-2201 in which the central indole ring has been replaced by indazole.
THJ-2201 acts as a full agonist with a binding affinity of 1.34 nM at CB1 and 1.32 nM at CB2 cannabinoid receptors.
THJ-2201 has been linked to at least one hospitalization and death due to its use.
It is classified as a Schedule I controlled substance in the United States.
It is also an Anlage II controlled drug in Germany.